2026-10-14T04:26:17Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33971368 2026-09-23T06:20:48Z category_7 portal_147 item_type_3 month_year_09_2026

Supplemental Material for: Drug persistence and treatment outcomes after switching from intravenous to subcutaneous vedolizumab in inflammatory bowel disease figshare admin karger (2628495) Samuel Schäfer (7055405) Katarina Pihl Lesnovska (25094806) Henrik Hjortswang (7055393) Medicine Medicine <p dir="ltr">Introduction: Subcutaneous (SC) vedolizumab (VDZ) offers an alternative to intravenous (IV) administration for maintenance therapy in inflammatory bowel disease (IBD); however, long-term real-world evidence after IV-to-SCtransition remains limited. This study evaluated long-term effectiveness, safety, pharmacokinetics, patient experience, treatment cost, and drug persistence following IV-to-SC switch.</p><p dir="ltr">Methods: In this single-center prospective cohort, 51 patients with Crohn’s disease (CD, n=27) or ulcerative colitis (UC, n=24) IV-to-SC transitionedand were followed for 24 months. Patients who declined switching continued IV therapy (n=24) and served as a control group. Clinical indices, fecal calprotectin (FCP), VDZ trough levels, and health-related quality of life (HRQoL) were assessed at baseline, and at 3, 12, and 24 months. Drug persistence was analyzedusing Kaplan–Meier and Cox regression models. </p><p dir="ltr">Results: SC persistence was 96%, 86%, and 76% at 3, 12, and 24 months, respectively, with no statistically significant difference compared with IV therapy.Clinical indices, biochemical remissionrates, andHRQoL remained stableover all time points following IV-to-SC switch. FCP increased modestly after 12 months in SC-treated CD patients, without a corresponding statistically significant deterioration in clinical indices or biochemical remission rates.VDZ trough levels increased after switchingand were associated with biochemical remission. Most patients experienced the IV-to-SC switch aspositive. </p><p dir="ltr">Conclusion: Switching from IV-to-SC VDZ wassafe, effective, and well accepted by patients.No statistically significant differences in two-year persistence, clinical, and biochemical outcomes were observed compared with continued IV therapy.SC VDZ is thus a viable, patient-centered maintenance option for IBD.</p> 2026-09-23T06:20:48Z Dataset Dataset 10.6084/m9.figshare.33971368.v1 https://figshare.com/articles/dataset/Supplemental_Material_for_Drug_persistence_and_treatment_outcomes_after_switching_from_intravenous_to_subcutaneous_vedolizumab_in_inflammatory_bowel_disease/33971368 CC BY 4.0